
At 16:00 CET on Wednesday Feb 23, 2022, Orphazyme will meet with the European Medicines Agency’s (EMA) special committee, the CHMP, to give a so-called ”oral explanation.”
The biotech company has been summoned by the EMA in connection with the approval process of Orphazyme’s biggest drug hope, its candidate arimoclomol, a potential treatment for neurodegenerative disease Niemann-Pick type C (NPC).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app